Ovid Therapeutics Inc (OVID)
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small-molecule medicines for brain disorders, with an emphasis on epilepsies and seizure-related neurological conditions in the United States. Its clinical pipeline includes OV329, a GABA-AT inhibitor being evaluated in Phase 1 studies for adult and infant drug-resistant epilepsies, and OV4071, an oral potassium-chloride cotransporter 2 activator in first-in-human Phase 1 trials for psychosis associated with Parkinson’s disease, Lewy body dementia, and acute schizophrenia. The company also maintains license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, Graviton, and Marinus Pharmaceuticals. Founded in 2014, Ovid Therapeutics is headquartered in New York, New York, and its common stock trades on the NASDAQ under the symbol OVID.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OVID
|
$2.32
|
-16.1% Downside
|
Fair
|
$5.92
|
114.3% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
2.5x
|
334.3x
|
539 M
|
277 M
|
2.3%
|
83.7%
|
12.0
|
158.9%
|
